In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60-85
SponsorUniversity Hospital, Geneva

About this trial

The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection. The immune response during the acute phase of the infection and after recovery will be compared to the immune response of asymptomatic Spn carriers as well as to the immune response of patients diagnosed with a viral respiratory infection (flu or respiratory syncytial virus (RSV)).

The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with bacterial/viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.

Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until discharge from the hospital or resolution of symptoms. During those visits, questions regarding symptoms will be asked.

Eligibility criteria

Qualifiers

Aged 60-85 years

Able to provide informed consent either independently or by a legal representative

Group 1 (Spn pneumonia patients): clinical and/or radiological signs of pneumonia

Group 1 (Spn pneumonia patients): positive Spn urinary antigen and/or blood culture and/or positive sputum test.

Disqualifiers

Immunosuppression,

Use of inhalation and/or nasal steroids the last month

Intubation or under invasive mechanical ventilation

Long-term antibiotic treatment prior to disease onset

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

280 Participants
are grouped into 3 trial groups

Sponsors and collaborators

University Hospital, Geneva

Lead sponsor

University of Geneva, Switzerland

Sponsor institution